Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X Artificial Intelligence & Technology ETF
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

Global X Artificial Intelligence & Technology ETF vs Cassava Sciences Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.04, while Cassava Sciences Inc trades at $1.34 (market cap $63.04M). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AIQFLNA
Sector
Sector/ThematicHealth
52-Week High
$70.14$4.64
52-Week Low
$43.28$1.16
Market Cap
$63.04M
Enterprise Value
-$23.53M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Artificial Intelligence & Technology ETF

AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.

The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.

Cassava Sciences Inc

FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.

The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.

Returns comparison

Trailing returns across standard periods

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA